Beijing Biostar Pharmaceuticals (HKG:2563) launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.
The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.
Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.
The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.
Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.
CCB International, China Securities International, ICBC, SPDB International, and several others are the joint book-runners of the IPO.
Price (HKD): $2761.00, Change: $+1.2, Percent Change: +0.04%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。